Kornimate/medical-research-clean huggingface dataset:
evaluation of the effect of palm olein free formula on intestinal flora and gastrointestinal tolerance

Conditions: Feeding; Disorder, Nonorganic Origin; Calcium Disorder; Intestinal Bacteria Flora Disturbance

Summary: depending on recent studies in literature the investigators aimed to compare whether gastrointestinal tolerance differs between infants fed with palm olein containing or palm olein free formulas. besides it is showed that palm olein containing formulas decreases the absorption of fat and calcium by forming insoluble calcium soaps. so it is suggested that intestinal flora might be affected as a reason of these specialties. this study also aimed to investigate with culture-independent methods whether feeding infants with palm olein free formula results in the modification of their intestinal microbiota in such a way that is similar to breastfed ones.

recent studies in literature the investigators aimed to compare whether gastrointestinal tolerance differs between infants fed with palm olein containing or palm olein free formulas. besides it is showed that palm olein containing formulas decreases the absorption of fat and calcium by forming insoluble calcium soaps. so it is suggested that intestinal flora might be affected as a reason of these specialties. this study also aimed to investigate with culture-independent methods whether feeding infants with palm olein free formula results in the modification of their intestinal microbiota in such a way that is similar to breastfed ones.

Eligibility criteria:
inclusion criteria: the data of the patients who fulfilled the following criteria are evaluated. 1. term infants between 38 and 40 weeks of gestational age and/or with a birth weight of \> 2500grams who are either breastfed or formula fed. selection of the subgroup using oral nutrition 2. feeding predominantly with palm olein free formula if presence in addition to breast milk for 8 weeks of life 3. feeding with other formulas including palm olein if presence in addition to breast milk for 8 weeks of life selection of the subgroup not using oral nutritional supplement (control group) 4. having similar demographical properties with infants feeding with breast milk (gender, age, weight, height) exclusion criteria: * infants with major congenital abnormalities will be excluded. * infants with lack of data will also be excluded. * infants, whose parents don't agree with informed consent, will be excluded.
compare the pharmacokinetics, pharmacodynamics and safety/tolerability of lc51-0255 film-coated tablet (sg85) with lc51-0255 uncoated tablet (sg82) in healthy subjects

Conditions: Ulcerative Colitis

Summary: to compare the pharmacokinetics, pharmacodynamics and safety/tolerability of lc51-0255 film-coated tablet (sg85) with lc51-0255 uncoated tablet (sg82) in healthy subjects.


Eligibility criteria:
inclusion criteria: 1. healthy males and females between the age of 19 and 45 at the screening visit 2. subjects with the body mass index (bmi) measurement results between 18.0 kg/m2 and 27.0 kg/m2 at the screening visit 3. subjects who were confirmed to be healthy based on the medical history 4. subjects who make a voluntary decision to participate in this clinical study and provide the informed consent exclusion criteria: 1. subjects with a clinically significant disease or history in liver, kidney, gastrointestinal system, respiratory system, musculoskeletal system, endocrine system, neuropsychiatric system, hemato-oncology system or cardiovascular system 2. subjects with a disease (e.g., crohn's disease, etc.) or history of surgery (except for simple appendectomy and herniotomy) in gastrointestinal system which may affect the absorption of the investigational product 3. subjects with a history of clinically significant disease or suspicious sign/symptom of ophthalmologic disease including uveitis and retinitis at the screening visit 4. subjects who had donated whole blood within 2 months, component blood within 1 month, or received transfusion within 1 month prior to the first administration day 5. subjects who had taken an inducer or inhibitor of drug metabolism such as barbiturates etc. within 1 month prior to the first administration day 6. subjects who had eaten grapefruit/caffeine-containing food within 3 days prior to the first hospitalization or subjects who could not stop taking food containing grapefruit or caffeine from 3 days prior to hospitalization to the discharge day 7. subjects who had taken any prescription drug or herbal medicine within 2 weeks or any over the counter (otc) drug within 1 week prior to the first administration day (however, subjects fulfilling other conditions could participate in the study at the investigator's discretion) 8. subjects who taking excessive caffeine or alcohol or heavy smoker (caffeine \> 5 units/day, alcohol \> 21 units/week (1 unit = 10 ml as pure alcohol), smoking \> 10 cigarettes/day) 9. subjects who had a history of tuberculosis (tb) infection or a positive result in the quantiferon tb-gold test and the chest x-ray in the screening tests 10. subjects who unable to take the food provided by the study institution 11. subjects who with a positive result in the serology test (hepatitis b test, human immunodeficiency virus (hiv) test, hepatitis c test, syphilis test) 12. other cases that the investigator consider unsuitable as the subject
respiratory depression during an analgosedation combining remifentanil and ketamine in tci for oocyte retrieval

Conditions: Oocyte Retrieval; Sedation, Conscious; Ventilatory Depression

Summary: this study evaluates the effect of the addition of ketamine to a conscious sedation protocol including remifentanil during oocyte retrieval. the investigators will have 2 groups with different target effect site concentrations, namely 150 ng/ml and 200 ng/ml.

the actual protocol for conscious sedation during oocyte retrieval in at the erasmus hospital (brussels) consists of remifentanil in tci-mode, with premedication by midazolam. however, episodes of bradypnaea with or without desaturation are still common. the primary objective is to observe if with the addition of ketamine, it is possible to significantly reduce the dose of remifentanil, in order to avoid episodes of respiratory depression caused by the opioid. the secondary outcomes measured, will be the pain levels experienced by the patient, the sedation level, and the satisfaction of the patients after the procedure.

Eligibility criteria:
inclusion criteria: * patients having an oocyte retrieval exclusion criteria: * bmi \> 30 * endometriosis * contraindications to ketamine

Keywords: ketamine remifentanil
alternate nostril breathing training in geriatrics with glaucoma and high blood pressure

Conditions: Primary Open Angle Glaucoma; Hypertension

Summary: hypertension, particularly if poorly controlled, appears related to an increased risk of open angle glaucoma, (the high tension type of glaucoma is characterized as optic nerve degeneration with ocular hypertension). so this study will search response of glaucoma to breathing exercise

hypertension, particularly if poorly controlled, appears related to an increased risk of open angle glaucoma, (the high tension type of glaucoma is characterized as optic nerve degeneration with ocular hypertension). with a random assignment, sixty hypertensive geriatric with high tension type primary open angle glaucoma will be assigned to breathing exercise (alternate nostril breathing) group (n=30 geriatrics) or waiting list geriatrics. the daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour).

Eligibility criteria:
inclusion criteria: * hypertensive elderly * primary open angle glaucoma in both eyes * ocular hypertension in both eyes exclusion criteria: acute or chronic eye inflammation cataract eye surgeries mental ill patients patients who will refuse to participate in the study other systemic /cardiovascular problem
propiverine in children suffering from non-neurogenic overactive bladder and urinary incontinence

Conditions: Overactive Bladder; Urinary Incontinence; Children

Summary: the study was conducted between 2004 and 2006 to prove efficacy and tolerability of the antimuscarinic propiverine compared to placebo in children suffering from non-neurogenic overactive bladder and urinary incontinence.

this clinical trial showed superior efficacy of propiverine over placebo and convincing tolerability for the treatment of children suffering from oab and urinary incontinence.

Eligibility criteria:
inclusion criteria: * voiding frequency 8 or above per day * at least one incontinence episode per day * age between 5-10 years * body weight between 17 and 45 kg exclusion criteria: * normal age expected bladder capacity * pvr more than 10 ml * dysfunctional voiding * neurogenic disorders * uti, constipation

Keywords: antimuscarinics children overactive bladder propiverine urinary incontinence urotherapy
anterior segment anatomic parameters for risk profiling of primary angle-closure glaucoma

Conditions: Glaucoma, Angle-Closure

Summary: the goal of this observational study is to examine the anterior segment anatomical parameters associated with the scleral spur and cornea for risk profiling of primary angle-closure glaucoma (pacg). the main question it aims to answer is: • are there new anatomical parameters of the anterior segment of the eye that can be used early for risk profiling for pacg? researchers will compare pacg and narrow angle groups to see if there are some anatomical parameters that can distinguish the two.

we aimed to examine the anterior segment anatomical parameters associated with the scleral spur and cornea for risk profiling of primary angle-closure glaucoma (pacg). this retrospective study included 84 patients with pacg and 84 patients with narrow angles (na). we collected parametric measurements obtained using anterior-segment optical coherence tomography and iolmaster 700. univariate and multivariate logistic regression models were used to compare the ocular parameters between the na and pacg groups as well as to identify risk factors for pacg. the predictive performance of each parameter was evaluated using the area under the receiver operating characteristic curve (auroc) analysis.

Eligibility criteria:
inclusion criteria: 1. primary angle-closure glaucoma （pacg) was defined as an occlusion angle with peripheral anterior synechiae and intraocular pressure (iop) \> 21 mmhg or associated with glaucomatous optic neuropathy. the following conditions were identified as possible glaucomatous optic neuropathies, including a vertical cup-to-disc ratio ≥ 0.6, vertical cup-to-disc ratio asymmetry ≥ 0.2, optic disc haemorrhage, and visible retinal nerve fibre layer defect. 2. participants with narrow angle (na) were selected from among patients with cataracts. na was defined as a trabecular-iris angle (tia) \< 15° on anterior segment optical coherence tomography, with the exclusion of glaucomatous optic neuropathy or visual field loss. exclusion criteria: (1) severe systemic disease, (2) secondary angle-closure glaucoma, (3) other ocular diseases, (4) history of intraocular surgery, and (5) unclear examination images.
thiazolidinediones (tzd) bone loss and the effects on bone marrow differentiation and osteoblast formation

Conditions: Osteoporosis

Summary: thiazolidinediones (tzds) are a commonly used antidiabetic drugs currently used by over a million patients in the united states. recent studies have shown that treatment with tzd may increase the risk of bone fractures. the cause of bone loss is not known. we believe that tzd may cause increased accumulation of fat in the bone marrow, which may cause decrease bone formation and weak bones. .

this study aims to determine if tzds increase the amount of fat and decrease the number of bone producing cells in the bone marrow. a total of 5 subjects who require surgery for mandible (jaw) fracture and bone graft will be recruited. some patients who will undergo mandible surgery will require a bone graft. in this procedure, a small piece of bone from the hip is placed in the mandible. in this study, a small amount of bone marrow fluid (5 ml or 1 teaspoon) will be obtained after the bone graft is completed. obtaining the bone marrow will not result in additional pain or health problems. the effect of tzd on bone marrow and bone forming cells will be studied. the cells obtained during surgery will be grown at dr beck's laboratory at emory university school of medicine. a working hypothesis suggests that the increased fracture risk in patients taking tzds is the result of tzds altering the differentiation capacity of bone marrow stromal cells pushing them towards the adipocyte lineage at the cost of osteoblast formation thereby decreasing bone formation. study aim:to determine whether tzd exposure in vitro alters bone formation and the differentiation capacity of bone marrow stromal cells by promoting adipocyte lineage differentiation and lowering osteoblast formation.

Eligibility criteria:
inclusion criteria: 1. males or females between the ages of 18 and 80 years undergoing ileac crest bone graft to repair traumatic mandible fracture. 2. patients admitted for elective or emergency surgery or trauma. exclusion criteria: 1. subjects with history of decompensated diabetes (blood glucose \> 200 mg/dl) 2. critically ill patients with multi-organ failure, relevant hepatic disease or impaired renal function (serum creatinine ≥ 2.0 mg/dl) 3. hiv 4. hemolytic anemia and/or hematocrit \< 28% 5. mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study 6. pregnancy

Keywords: investigate tzd exposure in vitro alters bone formation differentiation capacity bone marrow stromal cells
postprandial effects of mixed herbs and spices on pathways associated with glucose homeostasis and inflammation on pbmcs of healthy subjects

Conditions: Healthy

Summary: this study aims to investigate the effect of mixed of herbs and spices on gene expression of pathways associated with glucose homeostasis, oxidative stress, inflammation and its interrelation with circulating mirna, in the postprandial phase in healthy human subjects.


Eligibility criteria:
inclusion criteria: * healthy males and females * bmi 23-33 kg/m2 * must be able to accept spices * agreed and signed informed consent exclusion criteria: * below 18 years old * uncomfortable speaking english and/or difficulties in understanding spoken english * smoking or using snuss * vegetarian or vegan * having food allergies * stressed by venous blood sampling or previous experience of being difficult to be cannulated * receiving any drug treatment that may influence the study outcomes * pregnancy or breastfeeding

Keywords: spices functional food cardiometabolic risk metabolic syndrome inflammation peripheral blood mononuclear cell acute mirna
molecular and functional pet-fmri measures of analgesia in migraine

Conditions: Migraine; Healthy

Summary: the placebo effect is a phenomenon that has experienced major advances of its understanding in the last decade. however, mechanisms of placebo analgesia in chronic pain patients have yet to be compared to healthy subjects. the investigators study aims to investigate the magnitude of placebo response and related opioid release in patients that suffer from episodic migraines as compared to healthy controls. in particular, the investigators are looking to map brain activity during placebo analgesia using modern brain imaging techniques such as functional magnetic resonance imaging (fmri) and positron emission tomography (pet). the investigators hypothesis is that placebo response and the availability of opioid receptors is reduced in chronic migraine patients.


Eligibility criteria:
inclusion criteria: * migraine patients with aura with acute episodic migraine meeting the ihs classification ichd-ii criteria, 3-14 migraines per month. * history of episodic migraine for at least 3 years * ages 21-50 * male or female * right handed matched healthy subjects will also be recruited. exclusion criteria: * other significant disease (systemic or cns) * pregnancy * claustrophobia * weight \>235 lbs (limit of mri table) * significant drug including alcohol history (\> 7 glasses of alcohol per week) * beck depression inventory ii (bdi-ii) score \> 25 (moderate to severe depression) * any metal implants incompatible with mri (including dental bridges, crowns, retainers, orthodontic devices e.g. braces, iuds, aneurysm clips or other devices, tattoos containing metallic ink, cardiac pacemakers, prosthetic hear valves, other prostheses, neurostimulator devices, implanted infusion pumps, exposure to shrapnel or metal filings, cochlear implants, etc.) * previous significant research related exposure to ionizing radiation. * history of allergy or adverse reaction to opioids * significant medical history of such as seizure disorder, diabetes, alcoholism, cardiac disease including coronary artery disease, psychiatric problems; drug addiction, respiratory problems, liver disease, etc. * positive drug of abuse screen (excluding medications currently prescribed for their clinical condition, e.g. opioids, benzodiazepines, etc.) * patients with migraine \<72 hours prior to the experiments will not be included to ensure inter-ictal state. * opioids or preventative medication such as topiramate, ssris etc.

Keywords: migraine, headache, episodic, chronic, pain
a phase 2b, dose-range finding study of the efficacy and safety of multiple doses of gsbr-1290 in participants living with obesity or overweight with at least one weight-related comorbidity

Conditions: Obesity, Overweight, or Chronic Weight Management

Summary: this study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, pk, and pd of multiple doses of gsbr-1290 in participants living with overweight or obesity with at least one weight-related comorbidity. participants will be randomized to gsbr-1290 or placebo in a ratio of 3:1 within each cohort receiving multiple-ascending, qd doses of gsbr-1290 or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment.


Eligibility criteria:
inclusion criteria: * signed informed consent * bmi ≥30 kg/m2 or bmi ≥27.0 kg/m2 and previous/current diagnosis of ≥ 1 obesity related comorbidity exclusion criteria: * previous documented diagnosis of diabetes mellitus. * self-reported change in body weight \>5% within 3 months before screening * body weight ≤80 kg at screening * have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty, if performed \>1 year prior to screening)

Keywords: access, obesity, overweight, gsbr-1290, chronic weight management, obese, small molecule, glp-1 receptor agonist, structure therapeutics
study to assess the safety and efficacy of bol-303242-x ophthalmic suspension in dry eye syndrome

Conditions: Dry Eye Syndrome

Summary: the objective of this study is to identify the concentration and daily dosing frequency of bol-303242-x ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.


Eligibility criteria:
inclusion criteria: * subjects who have a diagnosis of dry eye disease. * intraocular pressure (iop) ≤28 mmhg with no iop lowering medications. * subjects who are willing and able to refrain from using contact lenses during the study. exclusion criteria: * subjects with known hypersensitivity or contraindication to any component of the study medication. * subjects who are expected to require concurrent treatment with ophthalmic medications (prescription or over the counter). * subjects who are expected to require treatment with corticosteroids during the study. * subjects who have used topical or systemic isotretinoin, cyclosporine, or retinoid therapies within 30 days prior to the screening visit. * subjects who have undergone any type of ocular surgery within three months prior to screening. * lacrimal punctal occlusion (plugs or cautery) within 2 months of screening visit. * subjects with a history or presence of chronic generalized systemic or ocular disease that the investigator feels might increase the risk to the subject or confound the result of the study.
multimodal analgesia versus routine care pain management

Conditions: Degenerative Disc Disease Lumbar; Spinal Stenosis; Lumbar Spondylolisthesis

Summary: most patients undergoing surgery experience significant post-operative pain. inadequate peri-operative pain management may decrease post-operative mobilization and increase length of hospitalization. additionally, poorly managed acute post-operative pain analgesia is associated with an increased risk of developing chronic pain and delayed wound healing. lumbar spine surgery is particularly painful, often requiring a multi-day hospitalization. the most common post-operative analgesia used in spine surgery is narcotic medication delivered via an intravenous patient controlled analgesia (iv pca). a multimodal peri-operative pain management protocol for spine surgery has the potential to not only decrease pain but also to improve recovery, decrease narcotic consumption, decrease length of stay in the hospital and reduce both direct and indirect hospital costs. the purpose of this study is to determine if post-operative pain and rate of recovery are improved in patients undergoing spine surgery using mma compared to usual analgesic care.

we hypothesize patients undergoing spinal fusion who receive peri-operative mma will have: 1. decreased post-operative pain compared to patients receiving usual care for pain management. 2. shorter hospital los compared to patients receiving usual care pain management. 3. fewer analgesic-related post-operative complications (urinary retention, ileus, etc) compared to patients receiving usual care pain management. 4. improved physical functioning at the time of hospital discharge compared to patients receiving usual care pain management. 5. better short and long term outcomes. subjects will be randomized to mma (group 1) or usual care (group 2). the unit of randomization will be a week (monday through sunday). each week will randomly be assigned to mma or usual care. subjects who are hospitalized into a consecutive week will continue with the pain regimen they were assigned upon hospitalization.

Eligibility criteria:
inclusion criteria: * patients undergoing single level mis-tlif * patients able to provide informed consent exclusion criteria: * allergies or other contraindications to medicines in the protocol * current liver disease with documented liver function test abnormality * current renal disese with documented glomerular filtration rate (gfr) \< 60 ml/min/1.73m2 * baseline (pre-operative) opioid use greater than 30 mg of morphine equivalents/day * active alcohol dependence * active illicit drug dependence

Keywords: multi-modal pain management lumbar fusion mistlif